Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Opicapone in Hepatic Impairment
NCT02101190Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2010
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration, Time to Reach Cmax and 1 more. Started Mar 2010; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02101190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101190.